Anti-DR5 Anticorps (A318924)

Tigatuzumab Biosimilar - Anti-DR5 Antibody - BSA and Azide free

Recombinant humanized monoclonal antibody to DR5.

ELISA

ELISA: 1:5,000-10,000

Human

Humanized

Monoclonal

IgG1

Unconjugated

Affinity chromatography.

Reconstitution dependent.

Reconstitute with distilled sterile water.

Lyophilized from sterile Phosphate Buffered Saline, pH 7.4. Normally 5%–8% Trehalose is added as a protectant before lyophilization.

Shipped at 4°C. Lyophilized: Store at -20°C to -80°C. Reconstituted: Aliquot and store at -80°C. Product is stable for one year. Avoid freeze/thaw cycles.

Prior to reconstitution, centrifuge the vial at 5,000g for 3-5 minutes at room temperature. Reconstitute with appropriate volume of distilled sterile water to bring product to 1mg/ml concentration. After addition of distilled sterile water, mix by gentle tapping. Note: It is not recommended to vortex or vigorously pipette the sample.

Apoptosis inducing protein TRICK2A/2B, Apoptosis inducing receptor TRAIL R2, CD262, CD262 antigen, Cytotoxic TRAIL receptor 2, Death domain containing receptor for TRAIL/Apo 2L, Death receptor 5, Fas like protein, KILLER, KILLER/DR5, OTTHUMP00000123492, OTTHUMP00000123493, p53 regulated DNA damage inducible cell death receptor(killer), TNF related apoptosis inducing ligand receptor 2, TNF-related apoptosis-inducing ligand receptor 2, TNFRSF10B, TR10B_HUMAN, TRAIL R2, TRAIL receptor 2, TRAIL-R2, TRAILR2, TRICK2, TRICK2A, TRICK2B, TRICKB, Tumor necrosis factor receptor like protein ZTNFR9, Tumor necrosis factor receptor superfamily member 10B, Tumor necrosis factor receptor superfamily, member 10b, ZTNFR9